When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009.

Where is Adaptive Biotechnologies located?

Adaptive Biotechnologies is located in Seattle, United States .

Who is the current CEO of Adaptive Biotechnologies?

Chad Robins is the current CEO of Adaptive Biotechnologies.

When was the latest funding round of Adaptive Biotechnologies?

Adaptive Biotechnologies's latest funding round was on Jan 22, 2018.

What is the annual revenue of Adaptive Biotechnologies?

Annual revenue of Adaptive Biotechnologies is $185M as on Dec 31, 2022.

Where does Adaptive Biotechnologies rank among its competitors?

Adaptive Biotechnologies ranks 2 amongst 294 active competitors.

Who are the top competitors of Adaptive Biotechnologies?

Adaptive Biotechnologies' top competitors are Moderna, Dynavax and Chimerix.

Adaptive Biotechnologies - 2025 Company Profile, Team, Funding, Competitors & Financials - Tracxn

Q: How many employees does Adaptive Biotechnologies have?

Adaptive Biotechnologies has 609 employees as of Dec 31, 2022.

Adaptive Biotechnologies is a public company based in Seattle (United States), founded in 2009 by Chad Robins and Harlan Robins. It operates as a Provider of clinical diagnostics, and drug discovery for immune diseases. Adaptive Biotechnologies has raised $419M in funding from Viking Global Investors and Matrix. The company has 294 active competitors, including 85 funded and 70 that have exited. Its top competitors include companies like Moderna, Dynavax and Chimerix.

Company Details

Provider of clinical diagnostics, and drug discovery for immune diseases. The company's immune profiling sequencing technology immunoSEQ enables the characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. Also, develops cell therapies, vaccines, and antibody molecules for infectious diseases.

Website: www.adaptivebiotech.com/
Social
Email ID: *****@adaptivebiotech.com, *****@adaptivebiotech.com
Phone Number: +1 **********

Key Metrics

Founded Year

2009

Location

Seattle, United States

Stage

Public

Total Funding

$419M in 16 rounds

Latest Funding Round

Series F, Jan 22, 2018, Undisclosed

Investors

Viking Global Investors & 22 more

Ranked

2^nd among 294 active competitors

Annual Revenue

$185M as on Dec 31, 2022

Employee Count

609 as on Dec 31, 2022

Investment & Acquisitions

Sequenta

Similar Companies

Moderna & 357 more

Exit Details

Public

Adaptive Biotechnologies is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ADAPTIVE BIOTECHNOLOGIES CORP CIN: 1478320 United States, Deadpooled	Nov 03, 2019	$185M (as on Dec 31, 2022)	-	-
ADAPTIVE BIOTECHNOLOGIES CORPORATION CIN: 270907024 Belgium, Active	Sep 07, 2009	-	609 (as on Dec 31, 2022)	-

Get your free copy of Adaptive Biotechnologies's company profile

Adaptive Biotechnologies has raised a total funding of $419M over 16 rounds. Its first funding round was on Dec 28, 2009. Its latest funding round was a Series F round on Jan 22, 2018 for an undisclosed amount. 1 investor participated in its latest round, which include Rock Springs Capital, Foresite Capital, HTIF and Orbimed.

Adaptive Biotechnologies has 23 institutional investors including Viking Global Investors, Matrix and Rock Springs Capital.

Here is the list of recent funding rounds of Adaptive Biotechnologies:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Jan 22, 2018	Undisclosed	Series F	9764607	9287385	Microsoft
May 06, 2015	$195M	Series F	4941844	6693492	Matrix, Rock Springs Capital, and 9 more
Jan 21, 2015	$94M	Series E	3822543	8925054	-

Access funding benchmarks and valuations. Sign up today!

View details of Adaptive Biotechnologies's funding rounds and investors

The founders of Adaptive Biotechnologies are Chad Robins and Harlan Robins. Chad Robins is the CEO of Adaptive Biotechnologies.

Here are the details of Adaptive Biotechnologies' key team members:

Chad Robins: Co-Founder & CEO of Adaptive Biotechnologies.
Harlan Robins: Co-Founder of Adaptive Biotechnologies.

View details of Adaptive Biotechnologies's Founder profiles and Board Members

Adaptive Biotechnologies' employee count trend

Adaptive Biotechnologies has 609 employees as of Dec 22. The total employee count is 111.0% more than what it was in Dec 21. Here is Adaptive Biotechnologies's employee count trend over the years:

Employee count trend for Adaptive Biotechnologies

Uncover Adaptive Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adaptive Biotechnologies include Moderna, Dynavax and Chimerix. Here is the list of Top 10 competitors of Adaptive Biotechnologies, ranked by Tracxn score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	BB Biotech, Gershon Capital & 30 others	80/100
2nd	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Rock Springs Capital, Foresite Capital & 21 others	78/100
3rd	Dynavax 1996, Berkeley (United States), Public	Developer of products to prevent and treat infectious and inflammatory diseases and cancer	$73.9M	Great Point Partners, InterWest Partners & 22 others	72/100
4th	Chimerix 2002, Durham (United Kingdom), Acquired	Developer of antiviral oral therapeutics	$95.2M	Aisling Capital, InterWest Partners & 12 others	66/100
5th	Novavax 1987, Gaithersburg (United States), Public	Developer of novel vaccines using nanoparticles and matrix adjuvant technology	-	Foresite Capital, Prospect Venture Partners & 13 others	65/100
6th	Generate Biomedicines 2018, Somerville (United States), Series C	CRO focused on drug discovery & development services	$643M	T. Rowe Price, Flagship Pioneering & 12 others	64/100
7th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	GIC, Arch Venture Partners & 7 others	62/100
8th	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	Perceptive Advisors, 5AM Ventures & 7 others	61/100
9th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Care Capital, Bay Partners & 9 others	61/100
10th	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	HBM Partners, Redmile Group & 12 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Adaptive Biotechnologies's competitors? Click here to see the top ones

Adaptive Biotechnologies has acquired Sequenta. Adaptive Biotechnologies has not made any investments as of now.

Here is the latest report on Adaptive Biotechnologies's sector:

Free

Oncology - Sector Report

Edition: January, 2025 (79 Pages)

View all reports related to Adaptive Biotechnologies

Media has covered Adaptive Biotechnologies for a total of 17 events in the last 1 year, 8 of them have been about company updates and 1 about partnerships.